ProArc Medical Ltd. is an early-stage medical device start-up dedicated to developing innovative, minimally invasive, and clinically effective devices for the field of urology.
The Company’s first product, ClearRing™, is designed to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), or enlarged prostate.


Serpin Pharma is a privately held biotech company developing a family of first-in-class
anti-inflammatory and immune-modulating peptide drugs derived from human alpha-1
antitrypsin. The peptide drugs have broad applications in inflammatory and autoimmune
diseases and represent a superior alternative to current alpha-1 antitrypsin for select
indications. Serpin’s research facilities are located in northern Virginia (United States).

Tubular Medical Ltd. is taking an innovative approach to reduce the bioburden (number
of bacteria present on a surface before sterilization) in patients with an endotracheal (ET)
tube. Although an ET tube is vital for safe and effective ventilation, currently available tubes present a significant drawback: Secretions, biofilms, and aerosolized medications that accumulate on the inner surface may cause increased airway resistance, acute tube obstruction, delayed weaning, and Ventilator Associated Pneumonia (VAP).

Tubular Medical introduces a proprietary, fully “peelable” inner surface technology for a simple and highly effective solution to accumulation in ET tubes.

Speech synthesis solutions (translating written text into spoken text) have yet to achieve a level that makes them indistinguishable from human speech.VivoText’s text-to-speech (TTS) engine delivers speech synthesis that is virtually indistinguishable from “real” human voices.
The engine is modeled after a proven technology called Music Objects Recognition (MOR), which was developed by VivoText’s founder.
           Development Stage            Revenue Stage          Public Companies          Holding Company